` NLSP (NLS Pharmaceutics AG) vs S&P 500 Comparison - Alpha Spread

NLSP
vs
S&P 500

Over the past 12 months, NLSP has underperformed S&P 500, delivering a return of -62% compared to the S&P 500's +14% growth.

Stocks Performance
NLSP vs S&P 500

Loading
NLSP
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
NLSP vs S&P 500

Loading
NLSP
S&P 500
Difference
www.alphaspread.com

Performance By Year
NLSP vs S&P 500

Loading
NLSP
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
NLS Pharmaceutics AG vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

NLS Pharmaceutics AG
Glance View

Market Cap
45.6m USD
Industry
Pharmaceuticals

NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder. The company is headquartered in Stans, Nidwalden and currently employs 6 full-time employees. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.

NLSP Intrinsic Value
0.278 USD
Overvaluation 64%
Intrinsic Value
Price
Back to Top